Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: A prospective randomized phase 3 study

Blood

Volumn 101, Issue 6, 2003, Pages 2144-2151

  Segeren, Christine M ^a,b   Sonneveld, Pieter ^a   Van der Holt, Bronno ^a   Vellenga, Edo ^a   Croockewit, Alexandra J ^a   Verhoef, Gregor E G ^a   Cornelissen, Jan J ^a   Schaafsma, Martijn R ^a   Van Oers, Marinus H J ^a   Wijermans, Pierre W ^a   Fibbe, Wim E ^a   Wittebol, Shulamit ^a   Schouten, Harry C ^a   Van Marwijk Kooy, Marinus ^a   Biesma, Douwe H ^a   Baars, Joke W ^a   Slater, Rosalyn ^a   Steijaert, Monique M C ^a   Buijt, Ivon ^a   Lokhorst, Henk M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; VINCRISTINE;

ADULT; AGED; ALLERGY; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; SKIN TOXICITY; URINARY TRACT DISEASE; VOMITING;

EID: 0037443390     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0889     Document Type: Article

References (38)

1. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208:1680-1685.
2. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994;330:484-489.
3. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992;10:334-342.
4. Group MTC. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol. 1998;16:3832-3842.
5. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2:822-824.
6. Selby PJ, McElwain TJ, Nandi AC, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol. 1987;66:55-62.
7. Attal M, Huguet F, Schlaifer D, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood. 1992;79:1130-1136.
8. Harousseau JL, Milpied N, Laporte JP, et al. Double-intensive therapy in high-risk multiple myeloma. Blood. 1992;79:2827-2833.
9. Barlogie B, Jagannath S, Vesole D, Tricot G. Autologous and allogeneic transplants for multiple myeloma. Semin Hematol. 1995;32:31-44.
10. Bjorkstrand B, Ljungman P, Bird JM, et al. Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation. Stem Cells. 1995;13(suppl 2):140-146.
11. Harousseau JL, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood. 1995;85:3077-3085.
12. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous blood stem cell transplantation in multiple myeloma: preliminary results of a randomized trial involving 167 patients. Stem Cells. 1995;13(suppl 2):156-159.
13. Bensinger WI, Rowley SD, Demirer T, et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol. 1996;14:1447-1456.
14. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131-3136.
15. Alegre A, Diaz-Mediavilla J, San-Miguel J, et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Espanol de Trasplante Hematopoyetico-GETH) and PETHEMA. Bone Marrow Transplant. 1998;21:133-140.
16. Lokhorst HM, Sonneveld P, Cornelissen JJ, et al. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant. 1999;23:317-322.
17. Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 2000;95:7-11.
18. Bjorkstrand B, Hagman A, Ljungman P, et al. Autologous stem cell transplantation in multiple myeloma-an update of the EBMT registry. VIII International Myeloma Workshop. Banff, Canada; 2001:141.
19. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.
20. Atkins CD. High-dose chemotherapy in multiple myeloma. N Engl J Med. 1996;335:1844-1845.
21. Attal M, Harousseau JL, Michaux JL, et al. Single versus double transplant in myeloma: a randomized trial of the Inter Groupe Francophone du Myelome (IFM). Blood. 2000;96:557a.
22. Cavo M, Tosi P, Zamagni E, et al. The "Bologna 96" clinical trial of single vs double PBSC transplantation for previously untreated MM: results of an interim analysis. VIII International Myeloma Workshop. Banff, Canada; 2001:29-30.
23. Fermand JP, Levy V, Ravaud P, et al. Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD-34 enriched ABSC: preliminary results of a two by two designed randomized trial in 230 young patients with multiple myeloma. VIII International Myeloma Workshop. Banff, Canada; 2001:147.
24. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
25. Segeren CM, Sonneveld P, van der Holt B, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol. 1999;105:127-130.
26. Lokhorst HM, Sonneveld P, Wijermans PW, et al. Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma. Br J Haematol. 1996;92:44-48.
27. ISCN. An international system for human cytogenetic nomenclature. In: Mitelman F, ed; Basel, Switzerland: Karger; 1995.
28. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
29. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Statistics in Medicine. 1882;1:121-129.
30. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789-793.
31. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.
32. Attal M, Harousseau JL, Facon T, et al. Single versus double transplant in myeloma: a randomized trial of the "Inter Groupe Francais du Myelome" (IFM). Blood. 1999;94:714a.
33. Goldschmidt H, Hegenbart U, Wallmeier M, et al. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncol. 1997;8:243-246.
34. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99:731-735.
35. Bjorkstrand BT, Svensson H, Goldschmidt H, et al. 5489 autotransplants in multiple myeloma-a registry study from the European Group for Blood and Bone Marrow Transplantation (EBMT). Blood. 1999;94:715a.
36. Zojer N, Konigsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95:1925-1930.
37. Konigsberg R, Zojer N, Ackermann J, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol. 2000;18:804-812.
38. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566-1571.